Tìm theo
Vecuronium
Các tên gọi khác (2) :
  • SID50112721
  • Vecuronium
Thuốc gây tê, mê
Thuốc Gốc
Small Molecule
CAS: 50700-72-6
ATC: M03AC03
ĐG : APP Pharmaceuticals , http://www.apppharma.com
CTHH: C34H57N2O4
PTK: 557.8274
Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C34H57N2O4
Phân tử khối
557.8274
Monoisotopic mass
557.431833322
InChI
InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
InChI Key
InChIKey=BGSZAXLLHYERSY-XQIGCQGXSA-N
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium
Traditional IUPAC Name
vecuronium
SMILES
[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
Độ tan chảy
228 °C
Độ hòa tan
1.86e-05 g/l
logP
0.89
logS
-7.5
pKa (Strongest Basic)
9.65
PSA
55.84 Å2
Refractivity
169.31 m3·mol-1
Polarizability
66.85 Å3
Rotatable Bond Count
6
H Bond Acceptor Count
3
H Bond Donor Count
0
Physiological Charge
2
Number of Rings
6
Bioavailability
1
MDDR-Like Rule
true
Dược Lực Học : Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.
Cơ Chế Tác Dụng : Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem] Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.
Dược Động Học :

▧ Metabolism :
100%
▧ Route of Elimination :
Fecal (40-75%) and renal (30% as unchanged drug and metabolites)
▧ Half Life :
51–80 minutes
Chỉ Định : Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
Tương Tác Thuốc :
  • Amikacin The agent increases the effect of muscle relaxant
  • Aminophylline Theophylline decreases the effect of muscle relaxant
  • Azathioprine The agent decreases the effect of the muscle relaxant
  • Betamethasone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Carbamazepine Decreases the effect of muscle relaxant
  • Clindamycin The agent increases the effect of muscle relaxant
  • Colistimethate Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
  • Corticotropin Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Cortisone acetate Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Dexamethasone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Fludrocortisone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Fosphenytoin Phenytoin decreases the effect of muscle relaxant
  • Gentamicin The agent increases the effect of muscle relaxant
  • Hydrocortisone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Lincomycin The agent increases the effect of muscle relaxant
  • Mercaptopurine The agent dereases the effect of the muscle relaxant
  • Methylprednisolone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Netilmicin The agent increases the effect of muscle relaxant
  • Oxtriphylline Theophylline decreases the effect of muscle relaxant
  • Phenytoin Phenytoin decreases the effect of the muscle relaxant
  • Piperacillin The agent increases the effect of the muscle relaxant
  • Polymyxin B Sulfate Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis.
  • Prednisolone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Prednisone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
  • Quinidine The quinine derivative increases the effect of the muscle relaxant
  • Quinine Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided.
  • Theophylline Theophylline decreases the effect of the muscle relaxant
  • Tobramycin The agent increases the effect of the muscle relaxant
  • Triamcinolone Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01339
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=39765
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507656
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07553
ChemSpider
http://www.chemspider.com/Chemical-Structure.36357.html
PharmGKB
http://www.pharmgkb.org/drug/PA164748865
Wikipedia
http://en.wikipedia.org/wiki/Vecuronium
Drugs.com
http://www.drugs.com/cdi/vecuronium.html
... loading
... loading